Healthcare PE Acquisitions: Patient Data and GDPR Compliance

Special Category Data: Why Healthcare Is Different

The GDPR establishes a clear hierarchy of data protection. Article 9 designates health data as a special category requiring explicit legal bases for processing that go well beyond standard consent or legitimate interest grounds. For Private Equity firms acquiring healthcare targets—whether private clinics, diagnostic laboratories, telehealth platforms, or pharmaceutical services—this classification fundamentally alters the risk profile of the transaction.

Health data encompasses not only clinical records but also genetic data, biometric data used for identification, and any information from which health status can be inferred. In practice, this extends to appointment histories, prescription records, insurance claim data, and even wellness application logs. Buyers frequently underestimate the breadth of data that falls within this classification, discovering post-acquisition that datasets previously categorised as routine operational data in fact constitute special category data requiring enhanced protections.

The regulatory consequences of misclassification are severe. Supervisory authorities across European Union member states have consistently imposed elevated fines for health data violations, reflecting the legislature's intent that special category data receive the highest standard of protection. For an acquiring fund, undisclosed or inadequately managed health data processing represents a quantifiable contingent liability that must be addressed during due diligence.

Health Data Processing Agreements and Legal Bases

Article 9(2) permits processing of special category data only under specific derogations. In healthcare contexts, the most commonly relied upon bases are explicit consent (Article 9(2)(a)), provision of health or social care (Article 9(2)(h)), and public interest in public health (Article 9(2)(i)). Each carries distinct requirements and limitations that directly affect the acquiring entity's ability to continue, modify, or expand data processing activities post-acquisition.

During due diligence, we consistently identify deficiencies in the documentation of legal bases for health data processing. A target may rely on patient consent obtained years ago under forms that predate current GDPR requirements, or may invoke the healthcare provision derogation without satisfying the national law conditions that member states impose as supplementary safeguards. In Italy, for instance, the Garante per la protezione dei dati personali has issued specific guidance on health data processing that imposes additional obligations beyond the directive-level requirements.

Buyers must require comprehensive mapping of all health data processing activities, the legal basis relied upon for each, and the supporting documentation. Where processing agreements with third-party processors exist—laboratory systems, cloud-hosted electronic health records, diagnostic imaging services—these must be assessed for Article 28 compliance and for alignment with the specific requirements applicable to special category data.

Patient Data Migration: The Critical Post-Acquisition Risk

Post-acquisition integration of healthcare targets invariably involves data migration: consolidating patient records into unified systems, transitioning to new electronic health record platforms, or integrating diagnostic data across acquired facilities. Each migration event constitutes a new processing activity that must independently satisfy Article 9 requirements and maintain the integrity and confidentiality of patient data throughout the process.

The technical risks of patient data migration are substantial. We have assessed migration projects where patient identifiers were inadequately mapped between systems, resulting in record duplication or, more critically, record conflation—where data from different patients is merged into a single record. Beyond the obvious clinical safety implications, such incidents constitute data breachesreportable under Article 33 and potentially notifiable to affected data subjects under Article 34, given the sensitive nature of the data.

Effective migration planning requires data quality assessment prior to migration, defined mapping protocols with validation checkpoints, rollback capabilities, and post-migration audit procedures. The timeline for safe patient data migration is typically twelve to twenty-four months—a factor that must be reflected in integration planning and, where relevant, in the purchase price adjustmentmechanisms of the transaction.

Data Protection Officer Requirements

Article 37 of the GDPR mandates appointment of a Data Protection Officer where the core activities of the controller involve processing special category data on a large scale. Healthcare entities processing patient data will almost universally meet this threshold. During due diligence, we assess not only whether a DPO has been appointed but whether the appointment satisfies the substantive requirements: professional qualifications, independence, adequate resourcing, and direct reporting to the highest management level.

A common finding in healthcare acquisitions is the appointment of a nominal DPO who lacks either the expertise or the organisational independence required by Articles 37 to 39. In several engagements, the DPO function was assigned to an existing compliance or IT manager as an ancillary responsibility, without additional training, dedicated time allocation, or structural independence from the data processing decisions they were tasked with overseeing. Such arrangements represent a compliance gap that supervisory authorities actively scrutinise.

Cross-Border Healthcare Acquisitions and Data Localisation

Healthcare PE acquisitions frequently involve multi-jurisdictional targets operating across several EU member states, or targets with operations in both EU and non-EU jurisdictions. Patient data is subject to both the GDPR framework and national health data legislation, which varies significantly between member states. France'sHébergement de Données de Santécertification, Germany's sector-specific health data rules, and Italy's Garante guidance each impose distinct requirements that a pan-European healthcare platform must satisfy simultaneously.

For PE firms pursuing buy-and-build strategies in European healthcare, the data architecture must be designed from the outset to accommodate these jurisdictional variations. Centralising patient data into a single platform without addressing national requirements creates immediate compliance exposure. The architectural decisions made during the first acquisition in a platform build have lasting consequences for the cost and feasibility of subsequent integrations.

Structuring the Transaction: Warranties and Indemnities

Given the elevated risk profile of health data processing, healthcare PE acquisitions require specific cyber and data protection warranty provisions beyond standard representations. These should cover: the completeness and accuracy of the data processing register, lawfulness of all special category data processing, compliance of processor agreements with Article 28, DPO appointment and independence, breach notification history and outstanding supervisory authority correspondence, and the status of any data protection impact assessments conducted or required under Article 35.

Indemnity provisions should address the specific risk of regulatory action arising from pre-acquisition processing activities, with particular attention to the extended limitation periods that supervisory authorities may apply to health data violations. Escrow mechanisms linked to completion of identified remediation activities provide additional protection. The objective is to ensure that the transaction structure reflects the true regulatory risk of the health data processing activities being acquired, rather than treating data protection as a generic compliance matter addressed through standard boilerplate.